{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-127535","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.505790+00:00","generated_at":"2026-06-26T03:51:39.553105+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ResMed Q3 revenue up 12% to $864.5M; non-GAAP EPS $1.32, up 2% YoY","bullets":["Revenue $864.5M (+12% YoY); constant currency growth 14%.","GAAP diluted EPS $1.22 (up from loss of $0.54); non-GAAP diluted EPS $1.32 (+2%).","Gross margin contracted 140 bps to 56.8%; non-GAAP gross margin contracted 150 bps to 58.1%.","Board declared $0.42/share dividend, record May 12, payable June 16, 2022.","CEO cites strong sleep/respiratory demand but supply chain disruptions limit ability to meet demand."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-127535","json":"https://secwatch.observer/filing/0001193125-22-127535.json","markdown":"https://secwatch.observer/filing/0001193125-22-127535.md","text":"https://secwatch.observer/filing/0001193125-22-127535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312522127535/0001193125-22-127535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312522127535/d319859d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:51:39.553105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}